GW Pharmaceuticals PLC- Price Target Increased to $147.00 by Analysts at Piper Jaffray (GWPH)
Research analysts at Piper Jaffray lifted their target price on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from $97.00 to $147.00 in a report released on Monday. Piper Jaffray’s price objective points to a potential upside of 65.08% from the company’s current price.
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up 0.35% on Monday, hitting $89.36. 88,462 shares of the company’s stock traded hands. GW Pharmaceuticals PLC- has a 1-year low of $10.20 and a 1-year high of $111.46. The stock has a 50-day moving average of $87.54 and a 200-day moving average of $73.48. The company’s market cap is $1.620 billion.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its earnings data on Wednesday, August 6th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($1.08) by $1.14. The company had revenue of $13.00 million for the quarter, compared to the consensus estimate of $12.88 million. The company’s quarterly revenue was up 5.6% on a year-over-year basis. On average, analysts predict that GW Pharmaceuticals PLC- will post $-1.91 earnings per share for the current fiscal year.
GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.